| 產(chǎn)品名稱 | PTEN-P8 |
|---|---|
| 商品貨號 | B210387 |
| Organism | Mus musculus, mouse |
| Tissue | Prostate epithelium |
| Product Format | frozen |
| Morphology | Epithelial-like |
| Culture Properties | adherent |
| Biosafety Level | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | Prostate cancer tumor |
| Age | 10 month |
| Gender | Male |
| Applications | PTEN signaling pathways and prostate cancer |
| Shipping Information | frozen |
| Storage Conditions | liquid nitrogen vapor phase |
| Karyotype | Chromosome Count: near 6N (113-125) Numerical Abnormalities: -1, -4, +10, +14, +15, +16, +17, -Y Structural Abnormalities: Der(2)T(2;11), Del(7C), Del(8A3), Del(10A1), Del(13B), Del(14C), Del(15B) |
| Images |  |
| Derivation | Prostate cancer tissue dissected from 10-month, intact Pten.loxp/loxp;PB-Cre4+ mouse |
| Receptor Expression | androgen receptor + |
| Comments | PTEN mutations are one of the the most frequent genetic alterations found in human prostate cancers. This cell line, PTEN-P8, along with its isogenic partner, PTEN-CaP8 was generated to better understand the underlying molecular mechanisms of PTEN in prostate cancer progression and control, as well as the signaling pathways controlled by PTEN. PTEN-P8 is heterozygous for Pten deletion. Down-regulation of the Cre transgene produces very low to undetectable levels of Cre protein expression in this cell line. This cell line was generated from tissue that had not been subjected to hormone ablation therapy and are thus ideal for the study of human refractory prostate cancer formation, as many of the most well-studied human prostate cancer cell lines are from late-stage cancer tissue that has undergone such therapy. |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated Dulbecco’s Modified Eagle’s Medium, (ATCC® No. 30-2002). To make the complete growth medium, add the following components to 500 ml of the base medium: fetal bovine serum (FBS; ATCC® No. 30-2020) to a final concentration of 10% 25 µg/mL bovine pituitary extract (BPE) 5 µg/mL human recombinant insulin 6 ng/mL human recombinant epidermal growth factor (EGF) Note: Do not filter complete medium |
| Subculturing | S/C when culture reaches ~70-85% confluence. A subcultivation ratio of 1:20 to 1:50 is recommended. 1. Remove and discard culture medium. 2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor. 3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes). Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal. 4. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting. 5. Add appropriate aliquots of the cell suspension to new culture vessels. An inoculum of 8.0 X 103 to 1.0 x 104 viable cells/cm2 is recommended. 6. Incubate cultures at 37°C. Renew medium every 2 to 3 days. |
| Culture Conditions | Temperature: 37°C Atmosphere: air, 95%; carbon dioxide (CO2), 5% |
| Population Doubling Time | approximately 14 hours |
| Name of Depositor | Dr. Jing Jiao & Dr. Hong Wu |
| Year of Origin | 2004 |
| 梅經(jīng)理 | 17280875617 | 1438578920 |
| 胡經(jīng)理 | 13345964880 | 2438244627 |
| 周經(jīng)理 | 17757487661 | 1296385441 |
| 于經(jīng)理 | 18067160830 | 2088210172 |
| 沈經(jīng)理 | 19548299266 | 2662369050 |
| 李經(jīng)理 | 13626845108 | 972239479 |
